Ratings Grifols, S.A. BME

Equities

GRF.P

ES0171996095

Market Closed - BME Other stock markets 09:05:10 03/05/2024 pm IST			5-day change	1st Jan Change
6.08 ^EUR	+2.18%		+2.10%	-42.37%

03/05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT
02/05	European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
With a P/E ratio at 11.74 for the current year and 8.09 for next year, earnings multiples are highly attractive compared with competitors.
The company appears to be poorly valued given its net asset value.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company is not the most generous with respect to shareholders' compensation.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GRIFOLS, S.A.	-42.37%	5.73B	-
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B	A-
BIOGEN INC.	-15.94%	31.67B	B-
UCB	+52.66%	24.62B	A
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B	C
INCYTE CORPORATION	-14.38%	12.07B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B	B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B	B+
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes